Zydus Cadila gets USFDA nod for Liothyronine Sodium Tablets to treat underactive thyroid
Ahmedabad: Pharma major, Zydus Cadila, has recently announced that the company has received final approval from the United States Food & Drug Administration (USFDA) to market Liothyronine Sodium Tablets USP, 5 meg, 25 meg, and 50 meg (US RLD: Cytomel Tablets).
Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 312 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila secures DCGI nod to start Phase III Clinical Trial of ZyCoV-D to prevent COVID
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
